UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.

UMN Pharma Inc. today announced that Shuichi Kanazashi, M.D. Ph.D., UMN's President & CEO, presented favorable results from a Phase I/II clinical study of UMN-0501, UMN Pharma's pandemic influenza recombinant Hemagglutinin vaccine candidate, at the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials (Geneva, February 12-13).